Cancer imaging company Kuva Labs is expanding its scope via the acquisition of solid tumor biotech Lisata Therapeutics.

NEOK Bio, Inc., an oncology therapeutics company focused on the development of novel antibody drug conjugates (ADCs) for ...

Boundless persevered with the other drug, a CHK1 inhibitor BBI-355, as a monotherapy for oncogene-amplified solid tumors. But the clinical data showed signs of hematological toxicity that would have ...

GT Biopharma submitted an IND application for GTB-5550 TriKE for solid tumors. Phase 1 trial planned for 2026.

In the summer of 2025, the University of Louisville Brown Cancer Center became one of the first in the US to offer FDA ...

Exelixis may only have one drug on the market right now, but with phase 3 results for a potential new blockbuster on the ...

Today some of the most aggressive solid tumor cancers remain stubbornly resistant to treatment. There are many reasons why these cancers are difficult to treat, including mutations they may express or ...

GT Biopharma targets a portion of the estimated $362 billion global solid tumor market Preliminary, unaudited cash balance of approximately $7 million as of December 31, 2025 anticipated to extend ...

A new study describes an alternative way of using the body’s own immune cells to treat cancer.

CAR T cells have made headlines for their ability to fight hematological cancers, but they have proven largely ineffective ...

A new single-cell profiling technique has mapped pre-malignant gene mutations and their effects in solid tissues for the ...

Gram-stained section of a macrophage with ingested S epidermidis bacteria, seen as purple granules within its cytoplasm. In this stain, the nucleus appears pale, with a reddish nucleolus. It is ...